Abstract
The role of the renin-angiotensin system (RAS) in the development of various malignancies has recently been extensively examined and, since it has been shown to significantly influence many aspect of cancer initiation and progression, the idea of RAS-targeted anticancer therapy has arisen. This article reviews the mechanisms underlying RAS-induced physiological and pathological responses related to cancer biology, including tumor growth, cell proliferation, apoptosis, angiogenesis, inflammation, and protein degradation, emphasizing the associated cellular transduction schemes activated by main RAS effectors. Also the dual nature of RAS-dependent effects, resulting from its complex physiology has been commented. Finally, based on the available data from clinical trials and experimental studies, the possibilities of the introduction of RAS-modulating drugs into standard clinical practice in oncology have been discussed with the focus on both, positive and negative effects associated with the administration of various classes of pharmaceuticals to cancer patients.
Keywords: The renin-angiotensin system, cancer therapy, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, transduction mechanisms.
Current Pharmaceutical Design
Title:The Renin-angiotensin System as a Target of Novel Anticancer Therapy
Volume: 19 Issue: 40
Author(s): Katarzyna Regulska, Beata Stanisz and Milosz Regulski
Affiliation:
Keywords: The renin-angiotensin system, cancer therapy, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, transduction mechanisms.
Abstract: The role of the renin-angiotensin system (RAS) in the development of various malignancies has recently been extensively examined and, since it has been shown to significantly influence many aspect of cancer initiation and progression, the idea of RAS-targeted anticancer therapy has arisen. This article reviews the mechanisms underlying RAS-induced physiological and pathological responses related to cancer biology, including tumor growth, cell proliferation, apoptosis, angiogenesis, inflammation, and protein degradation, emphasizing the associated cellular transduction schemes activated by main RAS effectors. Also the dual nature of RAS-dependent effects, resulting from its complex physiology has been commented. Finally, based on the available data from clinical trials and experimental studies, the possibilities of the introduction of RAS-modulating drugs into standard clinical practice in oncology have been discussed with the focus on both, positive and negative effects associated with the administration of various classes of pharmaceuticals to cancer patients.
Export Options
About this article
Cite this article as:
Regulska Katarzyna, Stanisz Beata and Regulski Milosz, The Renin-angiotensin System as a Target of Novel Anticancer Therapy, Current Pharmaceutical Design 2013; 19 (40) . https://dx.doi.org/10.2174/13816128113199990508
DOI https://dx.doi.org/10.2174/13816128113199990508 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Molecular Chaperone Disorders: Defective Hsp60 in Neurodegeneration
Current Topics in Medicinal Chemistry Patent Selections:
Recent Patents on Regenerative Medicine Clinical Evidence of Herb-Drug Interactions: A Systematic Review by the Natural Standard Research Collaboration
Current Drug Metabolism Inhibition of RET Activated Pathways: Novel Strategies for Therapeutic Intervention in Human Cancers
Current Pharmaceutical Design Growth Differentiation Factor-15 as a Biomarker of Obese Pre-diabetes and Type 2 Diabetes Mellitus in Indian Subjects: A Case-control Study
Current Diabetes Reviews Role of Genetic Factors in the Pathogenesis of Radial Deficiencies in Humans
Current Genomics Restoring the Dysfunctional Endothelium
Current Pharmaceutical Design Patent Selections:
Recent Patents on Regenerative Medicine Is Atherothromboaspiration a Possible Solution for the Prevention of No-Reflow Phenomenon in Acute Coronary Syndromes? Single Centre Experience and Review of the Literature
Current Vascular Pharmacology Heart Failure in South America
Current Cardiology Reviews Editorial (Thematic Issue: The Role of Creatine on Disease-Related Conditions)
Mini-Reviews in Medicinal Chemistry The Emerging Role of microRNA in Stroke
Current Topics in Medicinal Chemistry Safety Issues of Vitamin D Supplementation
Anti-Cancer Agents in Medicinal Chemistry Drug Eluting Stents in Interventional Cardiology - Current Evidence and Emerging Uses
Current Drug Targets - Cardiovascular & Hematological Disorders Novel Therapeutic Targets in Neuropsychiatric Disorders: The Neuroepigenome
Current Pharmaceutical Design Obstructive Sleep Apnea Syndrome: From Phenotype to Genetic Basis
Current Genomics Roles of Histone Deacetylases in Angiogenic Cellular Processes
Current Angiogenesis (Discontinued) Biomarkers in Molecularly Targeted Therapy for Cancer
Recent Patents on Biomarkers Genetic Signatures in the Treatment of Stroke
Current Pharmaceutical Design Oxygen Sensing, Cardiac Ischemia, HIF-1α and Some Emerging Concepts
Current Cardiology Reviews